en
Scientific article
English

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir

Published inSchweizerische medizinische Wochenschrift, vol. 142, w13516
Publication date2012
Abstract

Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitis C genotype 1. Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virological response rates to ~70% and allows to shorten treatment duration in ~½ of treatment-naïve patients with chronic hepatitis C genotype 1. Sustained virological response rates in treatment-experienced patients depend on the response to previous treatment, ranging from >80% in previous relapsers to ~30% in previous null responders. These advances come at the expense of new adverse effects and increased cost. In addition, treatment of chronic hepatitis C will become more complex. In these times of changing medical practice, the present expert opinion statement by the Swiss Association for the Study of the Liver shall provide guidance on the treatment of chronic hepatitis C with triple therapy comprising telaprevir or boceprevir.

Keywords
  • Antiviral Agents/administration & dosage/therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus/genetics
  • Hepatitis C, Chronic/drug therapy/genetics/virology
  • Humans
  • Oligopeptides/administration & dosage/therapeutic use
  • Proline/administration & dosage/analogs & derivatives/therapeutic use
  • Protease Inhibitors/administration & dosage/therapeutic use
  • RNA, Viral/genetics
  • Treatment Outcome
Citation (ISO format)
RUBBIA-BRANDT, Laura. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. In: Schweizerische medizinische Wochenschrift, 2012, vol. 142, p. w13516. doi: 10.4414/smw.2012.13516
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0036-7672
531views
0downloads

Technical informations

Creation03/26/2013 2:14:00 PM
First validation03/26/2013 2:14:00 PM
Update time03/14/2023 8:09:22 PM
Status update03/14/2023 8:09:22 PM
Last indexation01/16/2024 1:33:14 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack